Literature DB >> 21468144

Induction of immune tolerance in the treatment of rheumatoid arthritis.

Salvatore Albani1, Eva C Koffeman, Berent Prakken.   

Abstract

Progress in our understanding of the genetics and immunology of rheumatoid arthritis (RA) has translated into clinical practice with the introduction of a first generation of biologic agents that effectively interfere with the inflammatory cascade by blocking a key component. This evolution has not only changed the way we practice, but perhaps also the way we think about RA and its treatment. In our view direct manipulation of specific pathogenic pathways is increasingly being used to replace generalized pharmacological immune suppression. The next leap forward will be to develop therapeutic approaches that will lead to maintenance of disease remission with a minimal-treatment or even drug-free regimen, relying on the induction of immune tolerance rather than the suppression of the immune system. Immune tolerance has the potential to prevent tissue damage secondary to inflammatory responses while at the same time maintaining homeostasis through physiologic recognition of self and the ability to perceive and react to 'danger'. Novel therapeutic approaches are emerging from these concepts. Such therapies will hopefully be safe and efficacious, and will complement the first generation of biologic agents that are currently available.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468144     DOI: 10.1038/nrrheum.2011.36

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  92 in total

1.  Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells.

Authors:  Andrew M Platt; Vivienne B Gibson; Agapitos Patakas; Robert A Benson; Steven G Nadler; James M Brewer; Iain B McInnes; Paul Garside
Journal:  J Immunol       Date:  2010-07-02       Impact factor: 5.422

2.  Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes.

Authors:  Jeffry A Bluestone
Journal:  J Vis Exp       Date:  2007-08-20       Impact factor: 1.355

3.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Authors:  Geraldine Cambridge; William Stohl; Maria J Leandro; Thi-Sau Migone; David M Hilbert; Jonathan C W Edwards
Journal:  Arthritis Rheum       Date:  2006-03

4.  New and future agents in the treatment of rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

5.  T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles.

Authors:  A P Cope; S D Patel; F Hall; M Congia; H A Hubers; G F Verheijden; A M Boots; R Menon; M Trucco; A W Rijnders; G Sønderstrup
Journal:  Arthritis Rheum       Date:  1999-07

6.  A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

Authors:  Tamsin M Lindstrom; William H Robinson
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

7.  Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats.

Authors:  H S Thompson; N A Staines
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

8.  The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule.

Authors:  S Albani; J E Tuckwell; L Esparza; D A Carson; J Roudier
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

9.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

Review 10.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.

Authors:  Peter C Taylor; Marc Feldmann
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

View more
  11 in total

Review 1.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

2.  Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration.

Authors:  Gavin R Meehan; Hannah E Scales; Iain B McInnes; James M Brewer; Paul Garside
Journal:  Immunother Adv       Date:  2022-09-13

3.  Altered expression of intestinal human leucocyte antigen D-related and immune signalling molecules in juvenile idiopathic arthritis.

Authors:  M Arvonen; P Vähäsalo; S Turunen; H M Salo; M Mäki; K Laurila; O Vaarala; T J Karttunen
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

4.  Recognition of self-heat shock protein 60 by T cells from patients with atopic dermatitis.

Authors:  Berber Kapitein; Joost A Aalberse; Mark R Klein; Wilco de Jager; Maarten O Hoekstra; Edward F Knol; Berent J Prakken
Journal:  Cell Stress Chaperones       Date:  2012-08-07       Impact factor: 3.667

Review 5.  The eye: a window of opportunity in rheumatoid arthritis?

Authors:  Louis Tong; Julian Thumboo; York Kiat Tan; Tien-Yin Wong; Salvatore Albani
Journal:  Nat Rev Rheumatol       Date:  2014-06-10       Impact factor: 20.543

Review 6.  Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases.

Authors:  Yuya Takakubo; Yrjö T Konttinen
Journal:  Clin Dev Immunol       Date:  2011-10-27

7.  A case of mistaken identity: HSPs are no DAMPs but DAMPERs.

Authors:  Willem van Eden; Rachel Spiering; Femke Broere; Ruurd van der Zee
Journal:  Cell Stress Chaperones       Date:  2011-12-03       Impact factor: 3.667

Review 8.  T Cell-Mediated Chronic Inflammatory Diseases Are Candidates for Therapeutic Tolerance Induction with Heat Shock Proteins.

Authors:  Ariana Barbera Betancourt; Qingkang Lyu; Femke Broere; Alice Sijts; Victor P M G Rutten; Willem van Eden
Journal:  Front Immunol       Date:  2017-10-26       Impact factor: 7.561

Review 9.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

10.  A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP?

Authors:  Adrian M Shields; Gabriel S Panayi; Valerie M Corrigall
Journal:  Front Immunol       Date:  2012-02-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.